Hitta information om Orexo AB. Adress: Virdings Allé 32, Postnummer: 754 50.

Orexo AB (publ) har beslutat att genomföra återköp av egna aktier. Bolaget innehar per dagens datum inga återköpta stamaktier men 842 971

26-03, Karsten Slotte to resign from Scandi Standard's board at the annual general meeting 2021. Adress. Orexo AB BOX 303 751 05 Uppsala F-Skatt: Ja. Momsregistrerad: Ja. Bolagsform: Aktiebolag. Länssäte: Uppsala.

Orexo ab publ

Ethypharm acquires the rights to deprexis & vorvida in 4 European countries from our partner @GAIA_COM. Se hela listan på orexo.se Orexo strengthens IP rights for overdose rescue drug OX124. 27 January 2021 · Press Release. Key financial figures. Group net revenue. 663.6 MSEK. Last Twelve Months, Q120-Q420.

Mar 6, 2012 UPPSALA, Sweden-- Orexo AB is focusing its development activities to the three proprietary programs OX219, OX51 and OX27. The total

While revenues of kr664m were in line with analyst predictions, statutory losses were much smaller than expected, with Orexo losing kr2.45 per share. There's been a notable change in appetite for Orexo AB (publ) shares in the week since its yearly report, with the stock down 13% to kr60.40.Statutory earnings per share fell badly short of UPPSALA, Sweden, Feb. 1, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series of fixed income investor Orexo AB publ 4 years 6 months Senior Regional Sales Manager Orexo AB publ Oct 2019 - Present 1 year 6 months.

Uppsala – 5 februari, 2021 – Orexo AB (publ), (“Orexo” eller ”Bolaget”) (STO:ORX). (OTCQX:ORXOY) har idag meddelat samtliga innehavare av Bolagets

Acquisition of shares may only take place at a price within the price interval, on any occasion 2010-11-10 OREXO PUBL : launches deprexis® and vorvida® in the US and provides updated fin.. OREXO AB (PUBL) : Press releases relating to OREXO AB (PUBL) Investor relations | Deutsche Boerse AG: C5G | Deutsche Boerse AG 2021-03-22 Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden. Corporate Governance Orexo AB (publ)’s ISS Governance QualityScore as of March 31, 2021 is 7.

15.00 på IVAs Konferenscenter, Grev Turegatan 16, i Stockholm.
Cafe laguna hills

@OrexoABpubl. 8 April 2021. To avoid being captured in the vicious circle of #addiction there is a need of counselling support to cope with AUD… https://t.co/wcpUZLvlap. @OrexoABpubl.

Its products include Zubsolv tablets for the treatment Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
Åke grönberg

Our history. Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

Se hela listan på orexo.se Orexo strengthens IP rights for overdose rescue drug OX124. 27 January 2021 · Press Release.

Orexo fortsätter stärka patentskyddet för ZUBSOLV® · Uppsala - 17 mars, 2021 - Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY) meddelar idag att. US Patent

In their own names, insiders own kr102m worth of stock in the kr1.7b company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling. General Public Ownership. The general public holds a 33% stake in Orexo. Orexo AB (publ.) – delårsrapport januari-mars 2010 ons, maj 05, 2010 08:00 CET. Uppsala, 5 maj 2010 Fortsatt stark försäljningstillväxt för Abstral • Nettoomsättningen uppgick till 36,4 (114,9 MSEK).

Uppsala och vars aktie är noterad på Nasdaq OMX Stockholm. Report from Orexo AB’s annual general meeting, 13 April 2021 13 April 2021 · Press Release · Regulatory 23 March 2021 · RDV · Regulatory Orexo AB publ 2,620 followers 2w We welcome the recent guidelines published by the U.S. Department of Health and Human Services (HHS) to expand access to medication-assisted treatment (MAT) for Since its inception, Orexo has developed three pharmaceutical products that are commercialized by Orexo in the US or worldwide through partners. These products have been developed with a focus on innovative solutions to address patient need, mostly within opioid addiction and pain. Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB. Holds 1,741 shares and stock options/share awards entitling to 45,896 shares. 1.